keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/29676242/converting-oral-to-long-acting-injectable-antipsychotics-a-guide-for-the-perplexed-corrigendum
#1
Jonathan M Meyer
No abstract text is available yet for this article.
April 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29623634/a-review-of-clinical-and-economic-evaluations-applied-to-psychotropic-therapies-used-in-the-treatment-of-schizophrenia-in-argentina
#2
REVIEW
Gisela Paula González, Nebel Silvana Moscoso, Fernando Pablo Lago
Schizophrenia is considered a serious mental disorder that affects over 21 million people worldwide, and is associated with disability that frequently affects the patient's educational and working performance. In Argentina, two of the most widely used antipsychotics in the treatment of this disorder are haloperidol and risperidone. Both are provided free to patients without health coverage in public healthcare facilities. In this paper we seek to review the clinical and economic benefits of prescribing psychotropic therapies based on haloperidol (a first-generation antipsychotic that is part of the butyrophenone group of drugs) versus risperidone [an atypical or second-generation antipsychotic (neuroleptic) drug] in adult patients who have been diagnosed with schizophrenia...
October 23, 2017: PharmacoEconomics Open
https://www.readbyqxmd.com/read/29579528/decision-making-capacity-for-treatment-of-psychotic-patients-on-long-acting-injectable-antipsychotic-treatment
#3
Maria Nystazaki, Katerina Pikouli, Eva-Maria Tsapakis, Maria Karanikola, Dimitrios Ploumpidis, Giorgos Alevizopoulos
OBJECTIVE: Providing informed, consent requires patients' Decision-Making Capacity for treatment. We evaluated the Decision Making Capacity of outpatients diagnosed with schizophrenia and schizoaffective disorder on treatment with Long Acting Injectable Antipsychotic medication. METHOD: This is a retrospective, cross-sectional, correlational study conducted at two Depot Clinics in Athens, Greece. Participants included 65 outpatients diagnosed with schizophrenia and schizoaffective disorder on treatment with Long Acting Injectable Antipsychotics...
April 2018: Archives of Psychiatric Nursing
https://www.readbyqxmd.com/read/29569082/long-acting-injectable-second-generation-antipsychotics-an-update-and-comparison-between-agents
#4
REVIEW
Michael W Jann, Scott R Penzak
Schizophrenia is a chronic medical condition with periods of remission and relapses over a patient's lifetime. Antipsychotic medications represent the mainstay of treatment for this disease. Long-acting injectable (LAI) formulations of antipsychotics are an attractive alternative to their oral counterparts, as they enhance patient adherence. A number of second-generation antipsychotics (SGAs) are available in LAI formulations. These include paliperidone, aripiprazole, olanzapine, and risperidone. This article reviews the most recently developed and approved of these formulations-aripiprazole monohydrate, aripiprazole lauroxil, and paliperidone palmitate...
March 22, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29568276/effects-of-continuing-oral-risperidone-vs-switching-from-risperidone-to-risperidone-long-acting-injection-on-cognitive-function-in-stable-schizophrenia-patients-a-pilot-study
#5
Hikaru Hori, Asuka Katsuki, Kiyokazu Atake, Reiji Yoshimura
Objectives: Risperidone is the first new generation antipsychotic drug to become available as a long-acting injection (LAI). The purpose of this study was to evaluate the effects of switching from oral risperidone to risperidone LAI (RLAI) on cognitive function in stable schizophrenia patients compared with the effects of continuing oral risperidone. Methods: Sixteen stable patients who had received risperidone monotherapy for at least 3 months were enrolled (the RLAI group)...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29559781/novel-treatment-options-in-depression-and-psychosis
#6
REVIEW
Eva Ceskova, Petr Silhan
In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29506767/triple-advantages-of-injectable-long-acting-second-generation-antipsychotics-relapse-prevention-neuroprotection-and-lower-mortality
#7
Henry A Nasrallah
No abstract text is available yet for this article.
March 2, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29505193/long-acting-injectable-antipsychotics-where-do-they-fit-in-the-treatment-plan
#8
Christoph U Correll, John Lauriello
Long-acting injectable (LAI) antipsychotics have the potential to improve adherence and outcomes for patients with serious mental illness but are underused. Watch this Webcast to learn how to identify patients who may benefit from using LAIs, monitor treatment adherence, and use LAIs safely and effectively in patients with schizophrenia and related disorders.
January 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29492362/clozapine-improvement-of-negative-symptoms-of-schizophrenia
#9
Afaque H Khan, Samina Zaidi
We report five cases of treatment-resistant schizophrenia that presented with prominent negative and positive symptoms. They fulfill the criteria of diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5). They showed lack of response despite receiving multiple trials of first and second generation psychotropic agents. We decided to give these patients a trial of clozapine to improve their negative and positive symptoms as well as their quality of life...
December 20, 2017: Curēus
https://www.readbyqxmd.com/read/29490359/real-world-effectiveness-of-pharmacologic-treatments-for-the-prevention-of-rehospitalization-in-a-finnish-nationwide-cohort-of-patients-with-bipolar-disorder
#10
Markku Lähteenvuo, Antti Tanskanen, Heidi Taipale, Fabian Hoti, Pia Vattulainen, Eduard Vieta, Jari Tiihonen
Importance: Mood stabilizers and antipsychotics are the main maintenance treatments for bipolar disorder. Lithium is considered to be the most effective mood stabilizer, but very little is known about overall health outcomes associated with specific treatments and the comparative long-term effectiveness of specific psychotropics or routes of administration in the prevention of rehospitalizations. Objective: To study the comparative effectiveness of pharmacologic treatments in the prevention of rehospitalization in a nationwide cohort of patients with bipolar disorder...
February 28, 2018: JAMA Psychiatry
https://www.readbyqxmd.com/read/29457473/going-the-distance-reviewing-antipsychotic-depot-or-long-acting-injectable-treatments-in-australasia
#11
Theo Theodoros, Mark Taylor, Hannah Chu-Han Huang, Nancy Wang, Balaji Motamarri
OBJECTIVES: The aim of this study is to provide an opinion paper reviewing the role of depot or long-acting injectable (LAI) antipsychotic medications, with comments on individual newer LAIs such aripiprazole maintena and paliperidone palmitate. In particular, we share our recent experience of using paliperidone three-monthly LAI. We also reflect on the associated benefits and potential harms of LAIs, and when they may be used. CONCLUSIONS: LAI antipsychotics are an important and arguably under-utilised therapeutic option, particularly where medication adherence is a priority, and where an informed patient opts for this formulation...
February 1, 2018: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/29440904/discrepancy-in-taiwanese-psychiatrists-preferences-for-long-acting-injectable-antipsychotics-across-facilities-a-nationwide-questionnaire-survey
#12
Chun-Hao Liu, Po-Hsin Tsai, Ching-Yen Chen
Background: Although many studies have discussed psychiatrists' attitudes toward long-acting injectable antipsychotics (LAIs), no previous study has focused on differences in preference based on the facilities in which the psychiatrists practiced. Materials and methods: A pilot survey was conducted in a medical center in northern Taiwan, and a questionnaire was then distributed at the annual conference of the Taiwanese Society of Psychiatry in 2013. The questionnaire included general demographic data and preferences for the use of LAIs in different situations...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29402652/fall-risk-increasing-drugs-a-systematic-review-and-meta-analysis-ii-psychotropics
#13
Lotta J Seppala, Anne M A T Wermelink, Max de Vries, Kimberley J Ploegmakers, Esther M M van de Glind, Joost G Daams, Nathalie van der Velde
BACKGROUND AND OBJECTIVE: Falls are a major public health problem in older adults. Earlier studies showed that psychotropic medication use increases the risk of falls. The aim of this study is to update the current knowledge by providing a comprehensive systematic review and meta-analysis on psychotropic medication use and falls in older adults. METHODS AND DESIGN: This study is a systematic review and meta-analysis. A search was conducted in Medline, PsycINFO, and Embase...
February 2, 2018: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/29395607/a-quantitative-systems-pharmacology-study-on-optimal-scenarios-for-switching-to-paliperidone-palmitate-once-monthly
#14
Hugo Geerts, Athan Spiros, Patrick Roberts, Larry Alphs
Long-acting injectable (LAI) antipsychotic formulations are increasingly used for improving patient compliance and long-term outcomes. Transitioning to LAIs raises questions regarding how optimum efficacy can be rapidly achieved while minimizing potential efficacy and safety concerns related to overlapping plasma levels of prior treatments and the new LAI. Ideally, randomized clinical trials would provide guidance regarding transition algorithms, but the number of studies and sample size required to address relevant questions makes this approach unachievable...
January 25, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29381388/long-acting-injectable-atypical-antipsychotic-use-in-adolescents-an-observational-study
#15
Adriana Fortea, Daniel Ilzarbe, Laura Espinosa, Mireia Solerdelcoll, Clara de Castro, Giovanni Oriolo, Gisela Sugranyes, Inmaculada Baeza
OBJECTIVES: Although second generation long-acting injectable antipsychotics (SG-LAIAs) have been approved and are widely used in adults, there is limited evidence for the use of long-acting formulations in children and adolescents. Thus, we systematically describe the off-label use of SG-LAIAs in clinical practice in adolescent inpatients. METHODS: All individuals admitted to our Children and Adolescent Inpatient Psychiatry Unit receiving treatment with SG-LAIAs between January 2013 and June 2016 were reviewed...
January 30, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29379293/efficacy-and-safety-profile-of-paliperidone-palmitate-injections-in-the-management-of-patients-with-schizophrenia-an-evidence-based-review
#16
REVIEW
Robin Emsley, Sanja Kilian
The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the nonadherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29378547/the-research-and-evaluation-of-antipsychotic-treatment-in-community-behavioral-health-organizations-outcomes-reach-out-study-real-world-clinical-practice-in-schizophrenia
#17
Kruti Joshi, Lian Mao, David M Biondi, Robert Millet
BACKGROUND: Outpatient facilities, such as community behavioral health organizations (CBHOs), play a critical role in the care of patients with serious mental illness, but there is a paucity of "real-world" patient outcomes data from this health care setting. Therefore, we conducted The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) trial, a real-world, prospective, noninterventional observational study of patients with mental illness treated at CBHOs across the United States...
January 29, 2018: BMC Psychiatry
https://www.readbyqxmd.com/read/29350127/converting-oral-to-long-acting-injectable-antipsychotics-a-guide-for-the-perplexed
#18
Jonathan M Meyer
There has been increasing recognition that antipsychotic nonadherence is common across all stages of schizophrenia, starting from the first episode. Moreover, numerous meta-analyses of the existing literature indicate superiority of long-acting injectable (LAI) over oral antipsychotics when one adjusts for the greater illness severity and duration among patients in LAI antipsychotic trials. The increasing availability of LAI antipsychotic options has raised interest in converting patients from oral medication; however, the successful transition from oral to the comparable LAI antipsychotic requires an understanding of the current extent of antipsychotic exposure, the kinetics of the LAI preparation, and the expected plasma levels achieved by the LAI formulation...
December 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29345879/improving-long-term-outcomes-in-patients-with-schizophrenia-what-is-the-evidence-for-long-acting-injectable-antipsychotics
#19
Diana O Perkins
Do you consider long-acting injectable (LAI) antipsychotics when selecting among treatments for schizophrenia? Take part in this CME activity to review the evidence for LAIs vs oral medications and to learn which patients may benefit most from this treatment option. Plus, discover the pharmacokinetic properties of LAIs and barriers to their use.
November 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29343694/sertraline-paroxetine-and-chlorpromazine-are-rapidly-acting-anthelmintic-drugs-capable-of-clinical-repurposing
#20
Janis C Weeks, William M Roberts, Caitlyn Leasure, Brian M Suzuki, Kristin J Robinson, Heather Currey, Phurpa Wangchuk, Ramon M Eichenberger, Aleen D Saxton, Thomas D Bird, Brian C Kraemer, Alex Loukas, John M Hawdon, Conor R Caffrey, Nicole F Liachko
Parasitic helminths infect over 1 billion people worldwide, while current treatments rely on a limited arsenal of drugs. To expedite drug discovery, we screened a small-molecule library of compounds with histories of use in human clinical trials for anthelmintic activity against the soil nematode Caenorhabditis elegans. From this screen, we found that the neuromodulatory drugs sertraline, paroxetine, and chlorpromazine kill C. elegans at multiple life stages including embryos, developing larvae and gravid adults...
January 17, 2018: Scientific Reports
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"